◼ Archived
Business
Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere
Genmab releases new phase 2 data for its antibody-drug conjugate, prompting claims of superiority over rival treatments.
1 trends tracked about this subject — the full history, oldest to newest below.
Genmab releases new phase 2 data for its antibody-drug conjugate, prompting claims of superiority over rival treatments.